Given the limited treatment options in HCC and the availability of potential tools to recruit effector cells at the site of, and infiltrating the tumor, we therefore sought to explore whether NKG2D-ligands were shed into serum in patients with HCC, in what form, and whether they could have diagnostic or prognostic utility. The gene discussed is KLRK1; the disease is hepatocellular carcinoma.